The U.S. Food and Drug Administration granted approval for the commercialization of Eli Lilly and Company and Incyte Corporation’s Olumiant (baricitinib), setting a precedent for COVID-19 treatments.
Incyte Corporation reported that the U.S. Food and Drug Administration pushed back the review of the company’s supplemental New Drug Application for Opzelura (ruxolitinib cream) for vitiligo.
The U.S. Food and Drug Administration approved CTI BioPharma Corp.’s drug for treating adult patients with a type of bone marrow cancer who also have low blood platelet count.
Incyte Corporation withdrew the New Drug Application (NDA) for the company’s candidate drug for various types of lymphoma.
The U.S. health regulator expanded the emergency use authorization for Eli Lilly’s baricitinib for Covid-19, saying the arthritis medicine could now be used without taking Gilead’s drug remdesivir along with the product.
Incyte Corp. said on May 17 the company’s ruxolitinib cream to treat pigmentation disorder vitiligo met the main goal in a late-stage study.
The tenth annual Pharmaceutical Innovation Index, released April 21, sees Eli Lilly top the industry for the first time. The Pharmaceutical Invention Index, a ranking of the industry’s best pipelines, rated Bristol Myers Squibb as No. 1.
